title: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
abstract: A mouse/human chimeric monoclonal antibody (mAb) composed of the variable regions of murine 17-1A mAb and the constant regions of human IgG-1K immunoglobulin was administered to 10 patients with metastatic colon cancer. Four patients received single infusion of 10 mg (n = 2) or 40 mg (n = 2). Six patients received three infusion of 10 mg (n = 3) or 40 mg (n = 3) at 2-week intervals. The pharmacokinetics were similar at both dose levels and at the second and third infusions. The plasma disappearance curves were best fit by a two-compartment model having a mean alpha T1/2 of 17.5 hr (range 13-23 hr) and a mean beta T1/2 of 100.5 hr (range 65-139 hr). One patient who received three 40-mg doses of chimeric IgG-1K 17-1A mAb (day 0, 14, and 28) was the only patient to exhibit a detectable but modest antibody reactivity to chimera on days 63 and 84. The antibody reactivity was inhibited by murine 17-1A mAb, indicating that the antibody response was directed to the murine variable region of the chimera. The patients had no toxic or allergic reactions. This chimeric form of 17-1A mAb has an approximate 6-fold longer circulation time and appears to be substantially less immunogenic than its murine counterpart. These characteristics may provide an advantage in the clinical application of such chimeric molecules in therapeutic trials in humans.
authors.affiliation: Comprehensive Cancer Center, University of Alabama, Birmingham 35294.
authors.forename: A F
authors.initials: AF
authors.lastname: LoBuglio
authors.forename: R H
authors.initials: RH
authors.lastname: Wheeler
authors.forename: J
authors.initials: J
authors.lastname: Trang
authors.forename: A
authors.initials: A
authors.lastname: Haynes
authors.forename: K
authors.initials: K
authors.lastname: Rogers
authors.forename: E B
authors.initials: EB
authors.lastname: Harvey
authors.forename: L
authors.initials: L
authors.lastname: Sun
authors.forename: J
authors.initials: J
authors.lastname: Ghrayeb
authors.forename: M B
authors.initials: MB
authors.lastname: Khazaeli
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000235:genetics* / Q000627:therapeutic use; D002678:Chimera; D015179:Colorectal Neoplasms / Q000628:therapy*; D006801:Humans; D007127:Immunoglobulin Constant Regions / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D007700:Kinetics; D051379:Mice; D011863:Radioimmunoassay
chemical_list: D000911:Antibodies, Monoclonal; D007127:Immunoglobulin Constant Regions; D007135:Immunoglobulin Variable Region